Company intelligence / Profile preview
InBrain Pharma
Lille, Hauts-de-France, France
- Ownership
- Private
- Development stage
- Other
01
Overview
InBrain Pharma's lead program (A-dopamine) completed a Phase I/IIb trial, showing safety and efficacy for severe motor symptoms in advanced Parkinson's disease; a pivotal Phase 3 trial is set for 2026/2027. This technology enables continuous, titrated administration of dopamine directly into the brain, overcoming limitations of oral and systemic administration and aiming to personalize treatment for neurodegenerative disorders[1][2][3].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
UMR-S 1172 INSERM – University of LilleEA7365 University of LilleTricumed (Siromedes pumps)Flowonix (Prometra pumps)IDD-Xpert (CDMO, for GMP manufacture)
Beyond the preview
Go deeper on InBrain Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InBrain Pharma.